Building of the European Parliament in Brussels, © 123rf.com/Paul Grecaud

As a first result of the trilogue on the €100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.

Bio-ADM indicates endothelial dysfunction. Leaky blood vessels cause the huge drop in blood pressure preceding septic shock. Endothelial leakage is the reason for residual congestion in acute heart failure, leading to 25% of rehospitalisations within 30 days. Picture: Sphingotec GmbH

Pilot routine tests with the vasoactive biomarker bio-ADM confirm clinical test results. Medical leaders back actionable utility of the marker in medical decision-making in septic shock and congestive heart failure.

Biotechpharma invested €50m in its microbial facility expansion. © Biotechpharma UAB

Lituanian CDMO Biotechpharma UAB has invested €50m in order to expand its production capacity to 5000 litres.

Haematopoetic stem cells from the bone marrow. © 123rf.com/ royaltystockphoto

Kiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.

© University of Glasgow

Researchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.

Chronic inflammatory disease company Immunic Therapeutics starts Nasdaq-trade following merger with Vital Therapies.
 

Adherend Chinese hamster ovary (CHO) cells in cell culture flask (phase contrast microscopic view). Picture: Alcibiades

Biomanufacturing – either for production of biologics or bio-based everyday products – has traditionally suffered from the unpredictably variable response of production cell lines to external stimuli. Synthetic biology groups now wish to create a network of biofoundries that aim to establish reproducibility standards from process design to product purification and – in the long term – intend to switch from cell-based to cell-free bioproduction.

davidchiswellsml.png

IGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive Chairman effective immediately.

eb_2019_spring_josefplank.png

Within the record time of nine months, the Austrian government, together with experts of the Austrian Bioeconomy plattform and the sustainability think tank Denkstatt, has worked out a national bioeconomy strategy. European Biotechnology spoke with Josef Plank, Secretary General at the leading Federal Ministry of Sustainability about the focus and ambition of the national initiative.

A pensive mother. © C.D. Patel

Scientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.